What is HC Wainwright’s Estimate for SGMO FY2028 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Equities research analysts at HC Wainwright boosted their FY2028 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings per share of $0.64 for the year, up from their prior estimate of $0.63. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.51) per share.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the previous year, the business earned ($0.34) earnings per share.

Several other equities analysts have also recently issued reports on SGMO. Barclays upped their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday. StockNews.com raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday.

Sangamo Therapeutics Trading Down 4.7 %

Shares of Sangamo Therapeutics stock opened at $2.05 on Friday. The firm has a market capitalization of $427.67 million, a PE ratio of -2.73 and a beta of 1.10. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The firm’s 50 day moving average is $1.33 and its 200 day moving average is $0.86.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its holdings in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Sangamo Therapeutics during the second quarter worth about $67,000. Meritage Portfolio Management grew its position in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Sangamo Therapeutics in the 2nd quarter worth approximately $89,000. Finally, XTX Topco Ltd grew its holdings in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares in the last quarter. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.